Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  London Stock Exchange  >  AstraZeneca    AZN   GB0009895292

ASTRAZENECA (AZN)
Mes dernières consult.
Most popular
Report
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets

AstraZeneca : BEST OF THE BROKERS

share with twitter share with LinkedIn share with facebook
share via e-mail
0
09/15/2017 | 07:21am CET

Things are looking up for pharma giant Astrazeneca, Liberum analysts have said. Recent drug trials have driven the firm's shares back up to where they were before high-profile problems connected with the failure of lung cancer drug Imfinzi. Analysts downgrade the firm to a "hold" but hike Astra's target price to 5,000P.

Analysts from Cantor Fitzgerald praised home furnishings firm Dunelm for investing in growth over the last year. Such investment is paying dividends already, they say, with sales set to grow to over £2bn in the medium-term. Cantor brokers stick to their "buy" rating and target price of 780p.

(c) 2017 City A.M., source Newspaper

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on ASTRAZENECA
01:18p 3SBIO INC : China FDA Approves New Once-Weekly Bydureon to Improve Glycemic Cont..
01/15 ASTRAZENECA : BYDUREON BCise injectable medicine now available in the US for pat..
01/15 MERCK AND : AstraZeneca and Merck - U.S. FDA Approves LYNPARZA in Germline BRCA-..
01/15 ASTRAZENECA : Lynparza approved by US FDA in germline BRCA-mutated metastatic br..
01/13 ASTRAZENECA : Dong-A ST to develop anti-cancer drug candidates with AstraZeneca
01/13 ASTRAZENECA : U.S. FDA Approves LYNPARZA (olaparib) in Germline BRCA-Mutated Met..
01/13 MYRIAD GENETICS : Receives FDA Approval of BRACAnalysis CDx as Companion Diagnos..
01/13 ASTRAZENECA : FDA OKs first drug for breast cancer patients with gene flaw
01/12 ASTRAZENECA : US OKs 1st drug aimed at women with inherited breast cancer
01/12 ASTRAZENECA : LYNPARZA® (olaparib) Approved by US FDA in Germline BRCA-Mutated M..
More news
News from SeekingAlpha
11:35a FDA launches new program to boost transparency of clinical data used to suppo..
01/15 BIOTECH ANALYSIS CENTRAL PHARMA NEWS : Roche's MS Win, Aradigm FDA Panel Woes, A..
01/14 3 THINGS IN BIOTECH YOU SHOULD LEARN : January 13, 2018
01/14 WEEK IN REVIEW : Hua Medicine To Raise $200 Million Through Fundings And IPO For..
01/13 YOUR DAILY PHARMA SCOOP : Lipocine's Gloomy Future, Puma Labeling Change, Concer..
Financials ($)
Sales 2017 21 849 M
EBIT 2017 5 693 M
Net income 2017 2 297 M
Debt 2017 12 304 M
Yield 2017 3,87%
P/E ratio 2017 36,09
P/E ratio 2018 30,91
EV / Sales 2017 4,66x
EV / Sales 2018 4,65x
Capitalization 89 569 M
Chart ASTRAZENECA
Duration : Period :
AstraZeneca Technical Analysis Chart | AZN | GB0009895292 | 4-Traders
Technical analysis trends ASTRAZENECA
Short TermMid-TermLong Term
TrendsBullishBullishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 33
Average target price 68,7 $
Spread / Average Target -2,8%
EPS Revisions
Managers
NameTitle
Pascal Soriot Chief Executive Officer & Executive Director
Leif Valdemar Johansson Non-Executive Chairman
Pam P. Cheng Executive VP-Operations & Information Technology
Marc Dunoyer Chief Financial Officer & Executive Director
Sean Bohen Chief Medical Officer & Executive Vice President
Sector and Competitors
1st jan.Capitalization (M$)
ASTRAZENECA0.18%89 569
JOHNSON & JOHNSON4.32%391 587
NOVARTIS1.80%225 838
ROCHE HOLDING LTD.-0.28%218 350
PFIZER0.88%217 804
MERCK AND COMPANY4.25%159 987